TY - JOUR
T1 - Delayed Akt suppression in the lipopolysaccharide-induced acute lung injury promotes resolution that is associated with enhanced effector regulatory T cells
AU - Artham, Sandeep
AU - Verma, Arti
AU - Alwhaibi, Abdulrahman
AU - Adil, Mir S.
AU - Manicassamy, Santhakumar
AU - Munn, David H.
AU - Somanath, Payaningal R.
N1 - Funding Information:
This study was supported in part by National Heart, Lung, and Blood Institute Grant R01 HL103952, National Center for Advancing Translational Sciences Grant UL1 TR002378, and Wilson Pharmacy Foundation (intramural) and Translational Research Initiative grant (intramural). This work has been accomplished using the resources and facilities at the Veterans Affairs Medical Center in Augusta, GA. The funders had no role in the study design, data collection, analysis, or decision to publish the data. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.
Publisher Copyright:
© 2020 American Physiological Society. All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - The adaptive immune response could play a major role in the resolution of lung injury. Although regulatory T cells (Tregs) have been implicated in promoting the resolution of lung injury, therapeutic strategies to enhance Treg quantity and activity at the site of injury need further exploration. In the current study, Akt inhibition using triciribine (TCBN), given 48 h after lipopolysaccharide (LPS) administration, increased Tregs-promoted resolution of acute lung injury (ALI). TCBN treatment enhanced the resolution of LPS-induced ALI on day 7 by reducing pulmonary edema and neutrophil activity associated with an increased number of CD4+/FoxP3+/CD103+ and CTLA4+ effector Tregs, specifically in the injured lungs and not in the spleen. Treatment of EL-4 T-lymphocytes with two Akt inhibitors (TCBN and MK-2206) for 72 h resulted in increased FoxP3 expression in vitro. On the other end, Treg-specific PTEN knockout (PTENTreg KO) mice that have a higher Akt activity in its Tregs exhibited a significant impairment in ALI resolution, increased edema, and neutrophil activity associated with a reduced number of CD4+/FoxP3+/CD103+ and CTLA4+ effector Tregs as compared with the control group. In conclusion, our study identifies a potential target for the treatment of late-stage ALI by promoting resolution through effector Treg-mediated suppression of inflammation.
AB - The adaptive immune response could play a major role in the resolution of lung injury. Although regulatory T cells (Tregs) have been implicated in promoting the resolution of lung injury, therapeutic strategies to enhance Treg quantity and activity at the site of injury need further exploration. In the current study, Akt inhibition using triciribine (TCBN), given 48 h after lipopolysaccharide (LPS) administration, increased Tregs-promoted resolution of acute lung injury (ALI). TCBN treatment enhanced the resolution of LPS-induced ALI on day 7 by reducing pulmonary edema and neutrophil activity associated with an increased number of CD4+/FoxP3+/CD103+ and CTLA4+ effector Tregs, specifically in the injured lungs and not in the spleen. Treatment of EL-4 T-lymphocytes with two Akt inhibitors (TCBN and MK-2206) for 72 h resulted in increased FoxP3 expression in vitro. On the other end, Treg-specific PTEN knockout (PTENTreg KO) mice that have a higher Akt activity in its Tregs exhibited a significant impairment in ALI resolution, increased edema, and neutrophil activity associated with a reduced number of CD4+/FoxP3+/CD103+ and CTLA4+ effector Tregs as compared with the control group. In conclusion, our study identifies a potential target for the treatment of late-stage ALI by promoting resolution through effector Treg-mediated suppression of inflammation.
KW - Acute lung injury
KW - Akt
KW - PTEN
KW - Regulatory T cells
KW - Triciribine
UR - http://www.scopus.com/inward/record.url?scp=85082780243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082780243&partnerID=8YFLogxK
U2 - 10.1152/AJPLUNG.00251.2019
DO - 10.1152/AJPLUNG.00251.2019
M3 - Article
C2 - 32073894
AN - SCOPUS:85082780243
SN - 0363-6135
VL - 318
SP - L750-L761
JO - American Journal of Physiology - Heart and Circulatory Physiology
JF - American Journal of Physiology - Heart and Circulatory Physiology
IS - 4
ER -